The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
Abstract
Cisplatin resistance occurs, at least in part, through the function of the Fanconi anemia (FA)/BRCA pathway, a DNA-damage response pathway required for repair of cisplatin cross-links. In the current study, we designed a cell-based screening strategy to identify small-molecule inhibitors of the FA/BRCA pathway with the hypothesis that such molecules could restore sensitivity to platinum agents. We identified four inhibitors, including three protein kinase inhibitors (wortmannin, H-9, and alsterpaullone) and one natural compound (curcumin) that inhibit the FA/BRCA pathway. We show that curcumin, a compound that is generally regarded as safe, inhibits the monoubiquitination of the FANCD2 protein as predicted by the screen and consequently sensitizes ovarian and breast tumor cell lines to cisplatin through apoptotic cell death. We believe that this study shows an efficient, high-throughput method for identifying new compounds that may sensitize cancer cells to DNA-damaging chemotherapy. [Mol Cancer Ther 2006;5(4):952–61]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M. S., Timmers, C., Hejna, J., Grompe, M., & D'Andrea, A. D. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00173-3 · Cited by 1,198
Self-citationThe Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822
Self-citationThioredoxin Reductase Is Irreversibly Modified by Curcumin
Fang, J., Lu, J., & Holmgren, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414645200 · Cited by 521
The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J
Levitus, M., Waisfisz, Q., Godthelp, B. C., Vries, Y. D., Hussain, S., Wiegant, W. W., Elghalbzouri-Maghrani, E., Steltenpool, J., Rooimans, M. A., Pals, G., et al. (2005) · Nature Genetics · doi:10.1038/ng1625 · Cited by 432
Litman, R., Peng, M., Jin, Z., Zhang, F., Zhang, J., Powell, S., Andreassen, P. R., & Cantor, S. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.004 · Cited by 396
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia
Levran, O., Attwooll, C., Henry, R. T., Milton, K. L., Neveling, K., Rio, P., Batish, S. D., Kalb, R., Velleuer, E., Barral, S., et al. (2005) · Nature Genetics · doi:10.1038/ng1624 · Cited by 370
Cited by
Curcumin: From ancient medicine to current clinical trials
Hatcher, H., Planalp, R., Cho, J., Torti, F. M., & Torti, S. V. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7452-4 · Cited by 1,843
CURCUMIN: THE INDIAN SOLID GOLD
Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_1 · Cited by 1,647
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Self-citationDiscovery of curcumin, a component of golden spice, and its miraculous biological activities
Gupta, S. C., Patchva, S., Koh, W., & Aggarwal, B. B. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05648.x · Cited by 856
The Hox genes and their roles in oncogenesis
Shah, N., & Sukumar, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2826 · Cited by 835
Metadata
- Authors
- Chirnomas, D., Taniguchi, T., de la Vega, M., Vaidya, A. P., Vasserman, M., Hartman, A.-R., Kennedy, R., Foster, R., Mahoney, J., Seiden, M. V., & D'Andrea, A. D.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-04-01
- Volume
- 5
- Issue
- 4
- Pages
- 952-961
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2112791911
- Cited by
- 207
- References
- 6
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0493
- The paper
- Chirnomas, D., Taniguchi, T., de la Vega, M., Vaidya, A. P., Vasserman, M., Hartman, A.-R., Kennedy, R., Foster, R., Mahoney, J., Seiden, M. V., & D'Andrea, A. D. (2006). Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0493
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.